Literature DB >> 23239036

Mevalonate kinase genotype in children with recurrent fevers and high serum IgD level.

Achille Stabile1, Adele Compagnone, Salvatore Napodano, Carmela Gerarda Luana Raffaele, Maria Patti, Donato Rigante.   

Abstract

In selected cases, childhood's recurrent fevers of unknown origin can be referred to systemic autoinflammatory diseases as mevalonate kinase deficiency (MKD), caused by mutations in the mevalonate kinase gene (MVK), previously named "hyper-IgD syndrome" due to its characteristic increase in serum IgD level. There is no clear evidence for studying MVK genotype in these patients. From a cohort of 305 children evaluated for recurrent fevers in our outpatient clinic during the decade 2001-2011, we have retrospectively selected 10 unrelated Italian children displaying febrile episodes, associated with recurrent inflammatory signs (variably involving gastrointestinal tube, joints, lymph nodes, and skin) and persistently increased serum IgD levels. All these patients were examined for MVK genotype: only 2 presented bonafide MVK mutations, 5 showed the same S52N MVK polymorphism, while the remaining 3 had a wild-type MVK sequence. Clinical details of these patients have been reviewed through the critical analysis of their medical charts. Our report underscores the pitfalls of MKD diagnosis based on clinical grounds and IgD levels, emphasizing the uncertain contribution of MVK polymorphisms in the diagnostic assessment of the syndrome.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23239036     DOI: 10.1007/s00296-012-2577-z

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  9 in total

Review 1.  The plodding diagnosis of monogenic autoinflammatory diseases in childhood: from the clinical scenery to laboratory investigation.

Authors:  Donato Rigante; Ettore Capoluongo
Journal:  Clin Chem Lab Med       Date:  2011-01-31       Impact factor: 3.694

Review 2.  Genetics of monogenic autoinflammatory diseases: past successes, future challenges.

Authors:  Ivona Aksentijevich; Daniel L Kastner
Journal:  Nat Rev Rheumatol       Date:  2011-07-05       Impact factor: 20.543

3.  Hereditary periodic fever with systemic amyloidosis: is hyper-IgD syndrome really a benign disease?

Authors:  Rainer Siewert; Jörg Ferber; Rolf Dieter Horstmann; Christof Specker; Peter Julius Heering; Christian Timmann
Journal:  Am J Kidney Dis       Date:  2006-09       Impact factor: 8.860

4.  Hyperimmunoglobulinaemia D and periodic fever: a new syndrome.

Authors:  J W van der Meer; J M Vossen; J Radl; J A van Nieuwkoop; C J Meyer; S Lobatto; R van Furth
Journal:  Lancet       Date:  1984-05-19       Impact factor: 79.321

Review 5.  Hyper-IgD syndrome or mevalonate kinase deficiency.

Authors:  Monique Stoffels; Anna Simon
Journal:  Curr Opin Rheumatol       Date:  2011-09       Impact factor: 5.006

6.  Molecular analysis of the mevalonate kinase gene in a cohort of patients with the hyper-igd and periodic fever syndrome: its application as a diagnostic tool.

Authors:  A Simon; L Cuisset; M F Vincent; S D van Der Velde-Visser; M Delpech; J W van Der Meer; J P Drenth
Journal:  Ann Intern Med       Date:  2001-09-04       Impact factor: 25.391

Review 7.  The fresco of autoinflammatory diseases from the pediatric perspective.

Authors:  Donato Rigante
Journal:  Autoimmun Rev       Date:  2011-10-17       Impact factor: 9.754

8.  Diagnostic value of serum immunoglobulinaemia D level in patients with a clinical suspicion of hyper IgD syndrome.

Authors:  W Ammouri; L Cuisset; S Rouaghe; M-O Rolland; M Delpech; G Grateau; N Ravet
Journal:  Rheumatology (Oxford)       Date:  2007-09-05       Impact factor: 7.580

9.  Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome.

Authors:  Jeroen C H van der Hilst; Evelien J Bodar; Karyl S Barron; Joost Frenkel; Joost P H Drenth; Jos W M van der Meer; Anna Simon
Journal:  Medicine (Baltimore)       Date:  2008-11       Impact factor: 1.889

  9 in total
  5 in total

Review 1.  The labyrinth of autoinflammatory disorders: a snapshot on the activity of a third-level center in Italy.

Authors:  Luca Cantarini; Antonio Vitale; Orso Maria Lucherini; Caterina De Clemente; Francesco Caso; Luisa Costa; Giacomo Emmi; Elena Silvestri; Flora Magnotti; Maria Cristina Maggio; Eugenia Prinzi; Giuseppe Lopalco; Bruno Frediani; Rolando Cimaz; Mauro Galeazzi; Donato Rigante
Journal:  Clin Rheumatol       Date:  2014-06-24       Impact factor: 2.980

2.  "Hyper-IgD syndrome" or "mevalonate kinase deficiency": an old syndrome needing a new name?

Authors:  Fulvio Celsi; Alberto Tommasini; Sergio Crovella
Journal:  Rheumatol Int       Date:  2013-02-15       Impact factor: 2.631

3.  MMAB, a novel candidate gene to be screened in the molecular diagnosis of Mevalonate Kinase Deficiency.

Authors:  Massimo Mezzavilla; Ronald Rodrigues Moura; Fulvio Celsi; Paola Maura Tricarico; Sergio Crovella
Journal:  Rheumatol Int       Date:  2017-12-12       Impact factor: 2.631

4.  The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist.

Authors:  Micol Romano; Z Serap Arici; David Piskin; Sara Alehashemi; Daniel Aletaha; Karyl Barron; Susanne Benseler; Roberta A Berard; Lori Broderick; Fatma Dedeoglu; Michelle Diebold; Karen Durrant; Polly Ferguson; Dirk Foell; Jonathan S Hausmann; Olcay Y Jones; Daniel Kastner; Helen J Lachmann; Ronald M Laxer; Dorelia Rivera; Nicola Ruperto; Anna Simon; Marinka Twilt; Joost Frenkel; Hal M Hoffman; Adriana A de Jesus; Jasmin B Kuemmerle-Deschner; Seza Ozen; Marco Gattorno; Raphaela Goldbach-Mansky; Erkan Demirkaya
Journal:  Arthritis Rheumatol       Date:  2022-05-27       Impact factor: 15.483

5.  Dysregulation of the mevalonate pathway during SARS-CoV-2 infection: An in silico study.

Authors:  Juan Luis Gomez Marti; Alan Wells; Adam M Brufsky
Journal:  J Med Virol       Date:  2020-12-29       Impact factor: 20.693

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.